Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 13/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 10/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521737 | 0.88 | FGFR1 (0.43) | MAPTFGFR4FGFR1FGFR3FGFR2 | |
| SCHEMBL1521593 | 0.85 | FGFR1 (0.37) | FGFR4FGFR1FGFR3FGFR2KDR | |
| SCHEMBL1521831 | 0.84 | MAPT (0.46) | MAPTFGFR4FGFR1FGFR3FGFR2 | |
| SCHEMBL1521474 | 0.75 | FGFR4 (0.41) | FGFR4FGFR1FGFR3FGFR2 | |
| SCHEMBL1521504 | 0.75 | FGFR1 (0.41) | FGFR4FGFR1FGFR2 | |
| SCHEMBL1521894 | 0.74 | FGFR4 (0.41) | FGFR4FGFR1FGFR3FGFR2 | |
| SCHEMBL1521913 | 0.74 | FGFR4 (0.60) | MAPTFGFR4FGFR1FGFR3FGFR2 | |
| SCHEMBL1521473 | 0.72 | MAPT (0.44) | MAPTFGFR4FGFR1FGFR3FGFR2 | |
| SCHEMBL1521503 | 0.69 | FGFR4 (0.39) | FGFR4FGFR1FGFR3FGFR2KDR | |
| SCHEMBL1521677 | 0.68 | FGFR1 (0.38) | FGFR4FGFR1FGFR3FGFR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2063896-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008033999-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | MAPT 1608/4885FGFR4 1073/4885FGFR1 577/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | MAPT 1608/4885FGFR4 1073/4885FGFR1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.